<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e>-modified albumin (IMA)is a new biological marker of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies have found increased serum IMA levels after <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>, but no study has investigated the possibility that <z:hpo ids='HP_0001297'>stroke</z:hpo> modifies IMA blood levels </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: We studied 118 consecutive patients presenting within 3 h of the <z:hpo ids='HP_0003674'>onset</z:hpo> of an <z:hpo ids='HP_0011009'>acute</z:hpo> neurological deficit [84 brain infarctions (BI), 18 brain <z:mp ids='MP_0001914'>hemorrhages</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e>) and 16 <z:hpo ids='HP_0002326'>transient ischemic attacks</z:hpo> lasting less than 1 h or <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epileptic</z:e> <z:hpo ids='HP_0001250'>seizures</z:hpo>] </plain></SENT>
<SENT sid="3" pm="."><plain>Serum samples were obtained for <z:hpo ids='HP_0000001'>all</z:hpo> patients at initial presentation and repeated only in patients with <z:hpo ids='HP_0001297'>stroke</z:hpo> at 6, 12 and 24 h </plain></SENT>
<SENT sid="4" pm="."><plain>IMA was measured by the albumin-<z:chebi fb="240" ids="27638">cobalt</z:chebi>-binding test (<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> Technologies, Denver, Colo., USA) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The initial median IMA (bootstrap 95% confidence interval, CI) was 83 U/ml (79-86) and 86 U/ml (75-90) in patients with BI and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e>, respectively (p = 0.76), and was 73 U/ml (58-79) in others (p = 0.003 compared with BI, and p = 0.017 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>Baseline IMA levels correlated with the National Institutes of Health <z:hpo ids='HP_0001297'>Stroke</z:hpo> Scale [Spearman correlation coefficient: 0.34 (p = 0.002) in BI, 0.61 (p = 0.008) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e>] </plain></SENT>
<SENT sid="7" pm="."><plain>During the first 24 h, IMA levels increased in BI patients (median, 9.1%; bootstrap 95% CI, 5.2-11.5), whereas no change was observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICH</z:e> patients (median, 1.2%; bootstrap 95% CI, -7.8 to 6.8) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: IMA blood levels may be a biomarker for early identification of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Further studies are required to investigate the role of IMA in the early detection of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>